Carbapenemase Detection Among Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates Using a Modified Blue-Carba Test

Enty  Tjoa; Shikha Joon; Dianita  Angeline; Andrew  A. Lieputra; Daniel  Edbert; Lucky  Hartati Moehario

doi:10.35652/IGJPS.2022.12027

Authors

Enty Tjoa Department of Microbiology, School of Medicine and Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia. https://orcid.org/0000-0001-7187-4280
Shikha Joon Institutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China https://orcid.org/0000-0002-9178-962X
Dianita Angeline Department of Microbiology, School of Medicine and Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia. https://orcid.org/0000-0001-6121-7113
Andrew A. Lieputra Department of Microbiology, School of Medicine and Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia. https://orcid.org/0000-0002-8425-6470
Daniel Edbert Department of Microbiology, School of Medicine and Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia. https://orcid.org/0000-0001-6278-3256
Lucky Hartati Moehario Department of Microbiology, School of Medicine and Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia. https://orcid.org/0000-0003-4234-9932

DOI:

https://doi.org/10.35652/IGJPS.2022.12027

Keywords:

Acinetobacter baumannii, Blue-Carba Test (BCT), carbapenem-resistant A. baumannii (CRAB), antibiotic selection

Abstract

Objective: Acinetobacter baumannii is a Gram-negative opportunistic bacteria with carbapenemase-associated antibiotic resistance accounting for a majority of nosocomial infections globally. We sought to detect carbapenemase producers among carbapenem-resistant A. baumannii (CRAB) clinical isolates using Blue-Carba Test (BCT). Methods: This study was an observational descriptive study. At first, A. baumannii clinical isolates (142) were collected from January 2014 to September 2017 and stored at the Microbiology Laboratory of the Faculty of Medicine, Atma Jaya Hospital. Next step involved the identification of the carbapenem-resistant isolates using WHONET 5.3 software (https://whonet.org/software.html). Here, Imipenem and Meropenem served as markers. Finally, the identified carbapenem-resistant isolates were subjected to Blue-Carba Test. Results: Among 142 A. baumannii isolates, 51.4% (73/142) were identified as CRAB. Of these, 36 isolates were revived and all were found to be carbapenemase positive. Conclusion: Conclusively, a cent percent (36/36) prevalence of carbapenemase producers was observed in the CRAB group, which is an important clinical finding for antibiotic selection against A. baumannii infection. © 2022 iGlobal Research and Publishing Foundation. All rights reserved.